期刊文献+

重组hTRAIL腺病毒载体的构建及鉴定 被引量:2

Construction and Identification of Recombinant Adenovirus for Expression of hTRAIL
下载PDF
导出
摘要 目的构建表达hTRAIL基因的重组腺病毒载体。方法以重组质粒pThioHisA-TRAIL中提取的TRAIL基因为模板,采用PCR法扩增基因片段。将扩增的基因片段插入穿梭质粒pShuttle-CMV,并转化大肠肝菌DH5α。筛选重组质粒pShuttle-CMV-TRAIL,电转化已转化了pAdEasy-1的BJ5183细胞。筛选重组腺病毒质粒pAdEasy-TRAIL,用Lipofectamine转染293细胞,制备携带人全长TRAIL基因的重组复制缺陷型腺病毒(Ad-TRAIL)。氯化铯密度梯度离心法纯化Ad-TRAIL病毒颗粒,并测定病毒滴度。采用RT-PCR法检测TRAIL基因在293细胞中的转录。以Ad-TRAIL转染YTMLC细胞,采用免疫荧光法和流式细胞术检测TRAIL基因的表达。结果纯化后的Ad-TRAIL病毒颗粒数为2.77×1012VP/ml,感染性滴度为109.5(3.2×109)CCID50/ml。经RT-PCR扩增出约843bp的基因片段,与目的片段大小一致。流式细胞术和免疫荧光法均检测到TRAIL在YTMLC细胞中的表达,表达产物主要存在于细胞质中。结论已成功构建了表达hTRAIL重组腺病毒载体,为肿瘤的基因治疗提供了依据。 Objective To construct a recombinant adenovirus for expression of human TNF-related apeptosis inducing ligand (hTRAIL) gene. Methods Amplify gene fragment by PCR using the TRAIL gene extracted from recombinant plasmid pThioHisA- TRAIL as a template,insert into shuttle plasmid pShuttle-CMV and transform to E. coli DH 5α Screen recombinant plasmid pShutfleCMV-TRAIL and transform to competent BJ5183 cells previously transformed with pAdEasy-1. Screen recombinant plasmid pAdEasyTRAIL and transfect to 293 cells in mediation of Lipefectamine to prepare, replication-deficient adenovirus Ad-TRAIL carrying fulllength of hTRAIL gene. Purify the prepared Ad-TRAIL virus particles by density gradient centrifugation with cesium chloride and determine the titer. Determine the transcription of TRAIL gene in 293 cells by RT-PCR. Transfect YTMLC cells with Ad-TRAIL and determine the expression of TRAIL by IFA and flow cytometry. Results The virus particle count and titer of purified Ad-TRAIL were 2. 77 × 10^12 VP/ml and 10^9.5(3.2 × 10^9 ) CCID50/ml respectively. The gene fragment at a length of about 843 bp was amplified by RT- PCR from transfected 293 ceils, which was consistent with that expected. Both flow cytometry and IFA proved the expression of TRAIL protein in YTMLC cells, and the expressed product mainly existed in cytoplasm. Conclusion Recombinant adenovirus Ad-TRAIL for expression of hTRAIL was successfully constructed, which provided a basis for gene therapy of tumors.
出处 《中国生物制品学杂志》 CAS CSCD 2007年第9期637-641,共5页 Chinese Journal of Biologicals
关键词 肿瘤坏死因子相关凋亡诱导配体 重组腺病毒 基因治疗 构建 鉴定 TNF-related apeptosis inducing ligand (TRAIL) Recombinant adenovirus Gene therapy Construction Identification
  • 相关文献

参考文献13

  • 1Wiley SR,Schooley K,Smolak PJ,et al.Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity,1995,3(6):673-682.
  • 2Gura T.How TRAIL kills cancer cells,but not normal cells.Science,1997,277 (5327):768.
  • 3Ashkenazi A,Pai RC,Fong S,et al.Safety and antitumor activity of recombinant soluble Apo2 ligand.J Clin Invest,1999,104 (2):155-162.
  • 4Keane MM,Ettenberg SA,Nau MM,et al.Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.Cancer Res,1999,59 (3):734-741.
  • 5Bodmer JL,Meier P,Tschopp J,et al.Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL.J Biol Chem,2000,275 (27):20632-20637.
  • 6Evdokiou A,Bouralexis S,Atkins GJ,et al.Chemotherapeutic agents sensitize osteogenic sarcoma cells,but not normal human bone cells,to Apo2L/TRAIL-induced apoptosis.Int J Cancer,2002,99 (4):491-504.
  • 7Hernandez A,Wang QD,Schwartz SA,et al.Sensitization of human colon cancer cells to TRAIL-mediated apoptosis.J Gastrointest Surg,2001,5 (1):56-65.
  • 8Suzuki H,Hotta T,Koyama T,et al.Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents co-operatively induce apoptotic cell death in both sarcoma and myeloma cells.Anticancer Res,2003,23(4):3247-3253.
  • 9Huang X,Lin T,Gu J,et al.Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer Xenograft.Gene Ther,2002,9(20):1379-1386.
  • 10Jo M,Kim TH,Seol DW,et al.Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.Nat Med,2000,6(5):564-567.

二级参考文献5

  • 1Wiley SR, Schooley K, F,Smolak PJ, et al. Identification and characterization of a new menber of the TNF family that induces apoptods[J]. Immunity, 1995,3(6):673.
  • 2Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand,a new member of the tumor necrosis factor cytokine family [J] .J Biol Chem,1996,271(22) :12687.
  • 3Kayagaki N, Yamaguchi N, Nakayama M, et al . Type I intefferons(IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs [J].J Exp Med, 1999,189(9) :1451.
  • 4Gura T. How TRAIL kills cancer cells, but not normal cells [J].Science, 1997,277: 768.
  • 5Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[J]. J Clin Invest, 1999,104(2) : 155.

共引文献3

同被引文献42

  • 1Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-assoeiated viral vectors. Methods, 2002, 28 (2): 267-275.
  • 2Kugler S, Lingor P, Scholl U, et al. Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology, 2003, 311 (1): 89-95.
  • 3Smith A J, Schlichtenbrede FC, Tsehernutter M, et al. AAV-med-iated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther, 2003, 8 ( 11 ): 188-195.
  • 4Carter BJ. Adeno-associated virus and the development of adenoassociated virus vectors: a historical perspective. Mol Ther, 2004, 10 (6): 981-989.
  • 5Fischer AC, Beck SE, Smith CI, et aL Successful transgene expression with serial (loses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther, 2003, 8 (6): 918-926.
  • 6Sandalon Z, Bruckheimer EM, Lustig KH, et al. Secretion of a TNFR:Fc fusion protein following puhnonary administration of pseudotyped adeno-associated virus vectors. J Virol, 2004, 78 (22): 12355-12365,.
  • 7Flotte TR. Immune responses to recombinant adeno-associatedvirus vectors: putting preclinica| findings into perspective. Hum Gene Ther, 2004, 15 (7): 716-717.
  • 8Hoshijima M, lkeda Y, lwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med, 2002, 8 (8): 864-871.
  • 9Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno associated virus vectors. J Virol, 2000, 74 (6): 2777- 2785.
  • 10Chao H, Walsh CE. AAV vectors for hemophilia B gene therapy. Mt Sinai Med, 2004, 71 (5): 305-313.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部